References
- Abdel-RahmanOImmune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentialsCrit Rev Oncol Hematol201697657126321371
- MomtazPPostowMAImmunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayPharmacogenomics Pers Med20147357365
- HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
- LimTSChewVSieowJLPD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunityOncoimmunology20165e108514627141339
- RajanAKimCHeeryCRGuhaUGulleyJLNivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancersHum Vaccin Immunother20161292219223127135835
- BrahmerJRHammersHLipsonEJNivolumab: targeting PD-1 to bolster antitumor immunityFuture Oncol20151191307132625798726
- BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
- BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
- BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
- LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med2015373233426027431
- MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med20153731803181326406148
- RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
- WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
- National Cancer Institute[database on internet]Bethesda, MDNational Institutes of Health Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed February 16, 2017
- DickersinKBerlinJAMeta-analysis: state-of-the-scienceEpidemiol Rev1992141541761289110
- HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
- SwansonMSSinhaUKRationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current dataOral Oncol201551121525459157
- TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245422658127
- PetersJLSuttonAJJonesDRAbramsKRRushtonLContour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJ Clin Epidemiol2008611099199618538991
- MoherDLiberatiATetzlaffJAltmanDGThe PRISMA Group2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med67e100009719621072